Financial

Pharmaceutical companies transferred £259.2 million in non-research payments to UK healthcare professionals and organisations in 2024, with a further £554 million in research funding, totalling £813 million. A BMJ investigation found £156 million paid to NHS trusts between 2015 and 2022 had no public explanation. Over two-thirds of pharmaceutical funding to clinical commissioning groups went undeclared in Freedom of Information investigations.

Consultancy payments comprised over 70% of total value transferred to individual healthcare professionals. The disclosure system remains voluntary and self-regulated through the ABPI Code of Practice. The companies manufacturing the drugs are paying the clinicians who prescribe them, the organisations that commission them and the trusts that administer them.

Atorvastatin has been the single most dispensed drug in England every year since 2016. In 2023/24 it reached sixty-five million items, up from fifty-nine million in 2022/23. Cardiovascular drugs as a category account for thirty per cent of all community-dispensed items in England. Primary care diabetes prescribing alone reached £1.67 billion in 2023/24, a seventy-four per cent increase from £960 million in 2015/16. Total NHS medicines spend across community dispensing and hospitals was £18.5 billion in 2022/23.

The category hierarchy by dispensing volume is cardiovascular drugs at thirty per cent, central nervous system drugs at nineteen per cent and endocrine drugs including diabetes at eleven per cent. These three categories, all treating conditions that epidemiological evidence links to the post-war dietary transition, account for sixty per cent of all community prescribing by item count. No corresponding decline in chronic disease prevalence has accompanied this prescribing growth.

Antidepressant prescribing reached eighty-nine million items in 2023/24, a one hundred and nine per cent increase since 2010. Atorvastatin and antidepressants together represent approximately 154 million annual prescriptions in a country of 57 million adults. Both are prescribed to treat conditions for which lifestyle interventions have RCT evidence of comparable or superior effectiveness in controlled trials.

The Quality and Outcomes Framework is the pay-for-performance system that distributes approximately £800 million per year to GP practices in England. In 2025/26, the statin prescribing indicator rose from fourteen points to thirty-eight points. The cholesterol-to-target indicator rose simultaneously from sixteen to forty-four points. Combined across nine cardiovascular indicators, 141 QOF points, worth approximately £198 million nationally at the current rate of £220.62 per point, are now concentrated on lipid-lowering prescribing and monitoring. The per-patient statin payment at full achievement roughly doubled.

The mechanism is purely financial. A GP practice scoring maximum points on the cardiovascular cluster in 2025/26 earns approximately £41 per registered patient on the coronary heart disease register, compared with roughly £20 per patient two years prior. Achievement in 2023/24 was already at ninety-one per cent for the statin indicator, meaning the escalation primarily rewards activity that was already near-universal.

The QOF has no indicator rewarding remission from chronic disease, reduction in medication load, or dietary reversal of metabolic conditions. It measures processes: prescriptions issued, blood tests completed, registers maintained. A GP who helps a patient reverse type 2 diabetes through dietary change and discontinue four medications earns fewer QOF points than one who maintains those medications and meets the monitoring thresholds.

The Quality and Outcomes Framework is the NHS pay-for-performance system that links GP practice income to clinical indicators. In 2025/26, 141 points were concentrated across nine cardiovascular indicators, representing approximately £198 million in national payments at full achievement. The statin prescription indicator alone increased from fourteen points to thirty-eight. The cholesterol-to-target indicator rose from sixteen to forty-four points. Per-practice CVD payments approximately doubled to around £41 per registered patient at full achievement.

This means GPs receive substantially more income for prescribing statins and achieving cholesterol targets than for any dietary or lifestyle intervention. The framework contains no points for reversing a type 2 diabetes diagnosis, no points for reducing a patient's antidepressant dose and no points for eliminating processed foods from a patient's diet. The financial architecture shapes clinical behaviour. This is because incentives determine actions, not beliefs.

A GP practice with five thousand patients achieving full CVD QOF compliance earns approximately £205,000 annually from those nine indicators alone. The same practice earns nothing for a patient who reverses metabolic syndrome through dietary change. The system rewards pharmaceutical management of chronic disease and provides no equivalent reward for resolving it.

The Trussell Trust distributed 3.1 million emergency food parcels in 2023/24, up from approximately 26,000 in 2008/09. Over 1.1 million of those parcels went to children and 655,000 people used a food bank for the first time that year. This represents a 120-fold increase in 15 years.

The corporations donating to food bank networks are often the same ones profiting from the ultra-processed products that dominate food bank shelves. A 2022 peer-reviewed study documented how Coca-Cola, McDonald's and major supermarkets fund food charity while their business models contribute to the conditions making food banks necessary. The food bank has become a permanent feature of the UK food system, not a temporary response to crisis.

Diabetes costs the UK approximately £14 billion per year, comprising £10.7 billion in direct NHS treatment and £3.3 billion in lost productivity. This represents roughly 10% of the entire health budget for a single diet-related condition. Over 5.6 million people now live with diabetes in the UK and every week the condition leads to 184 amputations, 660 heart attacks and 930 strokes.

Sixty percent of direct costs go to treating complications, most of which are preventable through dietary intervention. The NHS Diabetes Prevention Programme has demonstrated that modest dietary changes and weight loss of 3.3 kilograms can prevent type 2 diabetes at a fraction of the lifetime treatment cost. Yet NHS spending on diabetes medication alone has doubled over the past decade to £1.92 billion per year.

UK consumers spend £300.4 billion annually on food and drink, the NHS England budget is £185.8 billion and the pharmaceutical wholesale sector turns over £65 billion. These are not independent figures. Obesity alone costs the NHS an estimated £12.6 billion per year in direct treatment, with the wider economic cost reaching £126 billion when productivity losses and informal care are included.

The food industry profits from products that generate chronic disease, the NHS absorbs the treatment costs and the pharmaceutical industry profits from lifelong medications managing symptoms. Each sector depends on the continued failure of the others to address the root cause. The structural logic of three interconnected markets operating exactly as designed explains the pattern entirely.

Over 150 private equity deals in UK healthcare have completed since 2021, representing approximately sixty percent of all healthcare mergers and acquisitions. PE firms now control major mental health providers including The Priory and Cygnet, supplying over 30% of NHS mental health inpatient beds. More than half of all children and teenagers' mental health beds and three of the five largest care home providers are PE-owned.

A BMJ systematic review of 55 studies across eight countries found PE ownership was most consistently associated with increased costs to patients and payers. Nine of twelve cost studies showed higher costs under PE ownership and twelve of 27 quality studies found harmful impacts. The financial model relies on leveraged buyouts, cost extraction and resale, a structure fundamentally at odds with long-term patient care.

UK private healthcare spending reached £13.8 billion in 2022, having grown at nearly double the rate of NHS funding over the preceding decade as waiting lists lengthened and NHS capacity deteriorated.

Private healthcare demand is concentrated among the working-age professional class who can afford the access premium. The result is a two-tier system where health outcomes correlate increasingly with income rather than clinical need.

The private sector draws clinical staff trained at public expense, reducing NHS workforce capacity further. The system is self-reinforcing: as the NHS declines, private demand rises, drawing more resource from the public sector that enabled the decline.

Healthy food costs nearly three times more per calorie than less healthy alternatives in the UK. The poorest tenth of households would need to spend 74% of their disposable income on food to meet government dietary guidelines. For these families, a nutritious diet is a mathematical impossibility given their income.

The price gap has widened, with healthier food increasing in price at twice the rate of less healthy options over recent years. The people most likely to develop diet-related disease are structurally prevented from affording the diet that would protect them. The system then treats their resulting conditions through the NHS at far greater cost.

The Quality and Outcomes Framework (QOF) is a pay-for-performance scheme that rewards GP practices for meeting clinical indicators. Cardiovascular disease prevention indicators pay practices approximately £180 per qualifying patient placed on a statin, and similar amounts for antihypertensives and diabetic medication. Across England, QOF payments for prescribing-linked indicators total over £150 million annually (NHS England, 2023). Practices can earn up to £70,000 to £120,000 per year from QOF.

This is because QOF indicators are defined around measurable prescription targets rather than health outcomes. The system counts whether a patient is on the drug, not whether the drug has improved their health. A GP practice receives the same payment for prescribing a statin to a patient who subsequently develops diabetes from the statin (OR 1.09, Sattar et al., 2010, Lancet) as for one who benefits. Lifestyle intervention, which the DPP trial showed is twice as effective as metformin, earns zero QOF points.

The system creates perverse incentives: a practice that counselled patients on diet, exercise and sleep instead of prescribing would lose QOF income. A practice that prescribed to every eligible patient regardless of clinical benefit would maximise income. The measurement framework rewards throughput of pharmaceutical interventions, not patient health outcomes. QOF was introduced in 2004 and has never been reformed to include lifestyle medicine indicators.

Schwartz and Woloshin (2019, JAMA) analysed pharmaceutical industry spending from 1997 to 2016 and found that marketing expenditures consistently exceeded research spending. In 2016, the industry spent $29.9 billion on medical marketing, of which $20.3 billion went to healthcare professionals and $6.0 billion to direct-to-consumer advertising. Total R&D spending was approximately $26.4 billion, meaning marketing outpaced research by $3.5 billion.

This is because the United States and New Zealand are the only two countries that permit direct-to-consumer pharmaceutical advertising. Kantar Media data shows pharmaceutical companies aired over 4.6 million television advertisements in 2018 alone, more than any other industry. A single 30-second prime-time placement costs $500,000 to $2 million.

The downstream effect is that prescription patterns follow marketing spend, not clinical evidence. Spurling et al. (2010, PLoS Medicine) reviewed 58 studies and found that pharmaceutical industry interactions with physicians were associated with higher prescribing rates, higher costs and lower prescribing quality. The doctor-patient relationship becomes a marketing channel subsidised by the patient through drug prices that include the cost of their own persuasion.